文献速递临床试验与 GCP基础与转化研究

心脏移植中供体心脏低温氧合灌注:随机对照开放标签多中心临床试验的短期结局

Hypothermic oxygenated perfusion of the donor heart in heart transplantation: the short-term outcome from a randomised, controlled, open-label, multicentre clinical trial.
PubMed 文献 · Lancet · 2024-01-01

该多国多中心随机对照开放标签优效性试验在8个欧洲国家15个移植中心纳入229例患者,比较供体心脏低温氧合机器灌注(HOPE)与静态冷储存(SCS)的安全性及优效性。主要终点为30天内复合终点,HOPE组19% vs SCS组30%(HR 0.56,95%CI 0.32-0.99;log-rank P=0.059),虽未达显著差异,但风险降低44%提示临床获益。

要点

  • HOPE组主要终点事件19% vs SCS组30%,HR 0.56(95%CI 0.32-0.99),log-rank P=0.059未达显著差异。
  • HOPE组原发性移植物功能障碍11% vs SCS组28%,风险比0.39(95%CI 0.20-0.73)。
  • HOPE组主要不良心脏移植事件18% vs SCS组32%,风险比0.56(95%CI 0.34-0.92)。

核心结论

  • 主要终点虽无显著差异,但HOPE相关的44%风险降低提示临床获益。
  • 以主要不良心脏移植事件衡量的移植后并发症减少。
  • 次要结局分析提示HOPE在减少原发性移植物功能障碍方面有益。

研究设计与样本

  • 多国、多中心、随机、对照、开放标签、优效性设计临床试验。
  • 在8个欧洲国家的15个移植中心开展。
  • 纳入18-70岁、无既往胸骨切开术、脑死亡后捐献的供体。
  • 共纳入229例患者,2020年11月25日至2023年5月19日入组。
  • 主要分析人群为204例接受移植的患者,HOPE组101例、SCS组103例。

主要发现

  • HOPE组主要终点19%(19/101)vs SCS组30%(31/103),风险降低44%(HR 0.56;95%CI 0.32-0.99;log-rank P=0.059)。
  • HOPE组原发性移植物功能障碍11%(11例)vs SCS组28%(29例),风险比0.39(95%CI 0.20-0.73)。
  • HOPE组严重不良事件63例(65%,158次)vs SCS组87例(70%,222次)。
  • HOPE组主要不良心脏移植事件18%(18例)vs SCS组32%(33例),风险比0.56(95%CI 0.34-0.92)。
  • HOPE组100个供体心脏经灌注后均可移植。

临床怎么用

  • 作者认为HOPE相关的44%风险降低提示临床获益。
  • 作者认为HOPE减少了以主要不良心脏移植事件衡量的移植后并发症。
  • 作者认为次要结局分析提示HOPE在减少原发性移植物功能障碍方面有益。
  • 作者认为HOPE应对供体心脏保存的现有挑战及供受体复杂性增加。
  • 作者提出未来研究将有助于进一步阐明HOPE的获益。

局限性

  • 主要终点未达统计学显著差异(log-rank P=0.059)。
  • 作者提出未来研究将有助于进一步阐明HOPE的获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Static cold storage (SCS) remains the gold standard for preserving donor hearts before transplantation but is associated with ischaemia, anaerobic metabolism, and organ injuries, leading to patient morbidity and mortality. We aimed to evaluate whether continuous, hypothermic oxygenated machine perfusion (HOPE) of the donor heart is safe and superior compared with SCS. METHODS: We performed a multinational, multicentre, randomised, controlled, open-label clinical trial with a superiority design at 15 transplant centres across eight European countries. Adult candidates for heart transplantation were eligible and randomly assigned in a 1:1 ratio. Donor inclusion criteria were age 18-70 years with no previous sternotomy and donation after brain death. In the treatment group, the preservation protocol involved the use of a portable machine perfusion system ensuring HOPE of the resting donor heart. The donor hearts in the control group underwent ischaemic SCS according to standard practices. The primary outcome was time to first event of a composite of either cardiac-related death, moderate or severe primary graft dysfunction (PGD) of the left ventricle, PGD of the right ventricle, acute cellular rejection at least grade 2R, or graft failure (with use of mechanical circulatory support or re-transplantation) within 30 days after transplantation. We included all patients who were randomly assigned, fulfilled inclusion and exclusion criteria, and received a transplant in the primary analysis and all patients who were randomly assigned and received a transplant in the safety analyses. This trial was registered with ClicalTrials.gov (NCT03991923) and is ongoing. FINDINGS: A total of 229 patients were enrolled between Nov 25, 2020, and May 19, 2023. The primary analysis population included 204 patients who received a transplant. There were no patients who received a transplant lost to follow-up. All 100 donor hearts preserved with HOPE were transplantable after perfusion. The primary endpoint was registered in 19 (19%) of 101 patients in the HOPE group and 31 (30%) of 103 patients in the SCS group, corresponding to a risk reduction of 44% (hazard ratio 0·56; 95% CI 0·32-0·99; log-rank test p=0·059). PGD was the primary outcome event in 11 (11%) patients in the HOPE group and 29 (28%) in the SCS group (risk ratio 0·39; 95% CI 0·20-0·73). In the HOPE group, 63 (65%) patients had a reported serious adverse event (158 events) versus 87 (70%; 222 events) in the SCS group. Major adverse cardiac transplant events were reported in 18 (18%) and 33 (32%) patients in the HOPE and SCS group (risk ratio 0·56; 95% CI 0·34-0·92). INTERPRETATION: Although there was not a significant difference in the primary endpoint, the 44% risk reduction associated with HOPE was suggested to be a clinically meaningful benefit. Post-transplant complications, measured as major adverse cardiac transplant events, were reduced. Analysis of secondary outcomes suggested that HOPE was beneficial in reducing primary graft dysfunction. HOPE in donor heart preservation addresses the existing challenges associated with graft preservation and the increasing complexity of donors and heart transplantation recipients. Future investigation will help to further elucidate the benefit of HOPE. FUNDING: XVIVO Perfusion.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Rega F, Lebreton G, Para M, et al. Hypothermic oxygenated perfusion of the donor heart in heart transplantation: the short-term outcome from a randomised, controlled, open-label, multicentre clinical trial. Lancet. 2024. PMID: 39153817. doi:10.1016/S0140-6736(24)01078-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。